Iovance Biotherapeutics, Inc. IOVA incurred a loss of 42 cents per share in first-quarter 2024, narrower than the Zacks Consensus Estimate of a loss of 45 cents. In the year-ago quarter, the company ...
Source LinkIovance Biotherapeutics, Inc. IOVA incurred a loss of 42 cents per share in first-quarter 2024, narrower than the Zacks Consensus Estimate of a loss of 45 cents. In the year-ago quarter, the company ...
Source Link
Comments